Impact of potential multiple drug-drug interactions on the adverse event profile of patients with hepatitis C treated with pangenotypic direct-acting antivirals in Spain
Authors:
Open Access
- 5 November 2024
- journal article
- research article
- Published by Esmon Publicidad, SA in Revista Espanola de Sanidad Penitenciaria
- Vol. 26 (3) , 98-112
Abstract
Objectives: Direct-acting antivirals (DAAs) share pharmacokinetic pathways with many comedications commonly administered to patients living with chronic hepatitis C virus (HCV) infection (PLWHCV). International guidelines recommend a thorough drug-drug interaction (DDI) risk assessment prior to starting DAA therapy and before starting comedications. This study aims to evaluate the impact of potential multiple DDIs in the real-life adverse event (AE) profile of PLWHCV treated with DAAs. Material and method: This is a retrospective, observational study using electronic medical records. Patients included were PLWHCV and were treated with either the protease inhibitor (PI) free DAA sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB) between 2017 and 2020. Potential (single and multiple) DDIs were identified using the Liverpool HEP Interaction Checker. AEs potentially associated to DDIs were identified during DAA treatment period. Results: 1620 patients with DAA prescriptions (SOF/VEL or GLE/PIB) were included. Of these, 123 were predicted to have multiple DDIs (multi-DDI). About 10% (123/1256) of the patients receiving ≥2 comedications were at risk of multi-DDI with DAA. Most comedication-associated AEs were recorded in this multi-DDI population (88.9%, 16/18), meaning that 13% (16/123) of the multi-DDI population suffered AEs. According to DAA regimen, more comedication-associated AEs were reported in GLE/PIB-treated as compared with SOF/VEL-treated patients (18.3% [13/71] vs 5.8% [3/52] p<0.05). These AEs were mainly reported by primary care physicians (62.5%). Discussion: PLWHCV predicted to have multiple DDIs are at high risk of AEs. Moreover, fewer comedication-associated AEs were identified with the PI-free DAA SOF/VEL as compared with GLE/PIB.Keywords
This publication has 29 references indexed in Scilit:
- Drug-Drug Interactions Potential of Direct-Acting Antivirals for the treatment of Chronic Hepatitis C Virus infectionInternational Journal of Antimicrobial Agents, 2020
- Hepatitis C virus infection and the role of a pharmaceutical care programAmerican Journal of Health-System Pharmacy, 2019
- Prevalencia de las potenciales interacciones medicamentosas entre los antivirales de acción directa pangenotípicos y la medicación concomitante asociada a los pacientes con infección del virus de la hepatitis C crónica en EspañaGastroenterología y Hepatología, 2019
- Prevalence and sociodemographic disparities of Hepatitis C in Baby Boomers and the US adult populationJournal of Infection and Public Health, 2019
- The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C InfectionDrug Metabolism and Disposition, 2018
- Oral Direct-Acting Agent Therapy for Hepatitis C Virus InfectionAnnals of Internal Medicine, 2017
- Managing drug–drug interactions with new direct‐acting antiviral agents in chronic hepatitis CBritish Journal of Clinical Pharmacology, 2016
- Drug–Drug Interactions Between Direct-Acting Antivirals and Psychoactive MedicationsClinical Pharmacokinetics, 2016
- A clinician's guide to drug‐drug interactions with direct‐acting antiviral agents for the treatment of hepatitis C viral infectionHepatology, 2015
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987